Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation

BACKGROUND: Phase III trials evaluating the efficacy of gefitinib (IRESSA) in non-small cell lung cancer (NSCLC) lend support to the need for improved patient selection in terms of gefitinib use. Mutation of the epidermal growth factor receptor (EGFR) gene is reported to be associated with clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Noro, Rintaro, Gemma, Akihiko, Kosaihira, Seiji, Kokubo, Yutaka, Chen, Mingwei, Seike, Masahiro, Kataoka, Kiyoko, Matsuda, Kuniko, Okano, Tetsuya, Minegishi, Yuji, Yoshimura, Akinobu, Kudoh, Shoji
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698934/
https://www.ncbi.nlm.nih.gov/pubmed/17150102
http://dx.doi.org/10.1186/1471-2407-6-277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698934/
https://www.ncbi.nlm.nih.gov/pubmed/17150102
http://dx.doi.org/10.1186/1471-2407-6-277

Ejemplares similares